A Study of HY-0102 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety,
tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients
with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and
obtain the preliminary efficacy information of patients with advanced solid tumors.